Guillain-Barré syndrome medical therapy

Revision as of 17:22, 20 December 2018 by Fahimeh Shojaei (talk | contribs)
Jump to navigation Jump to search

Guillain-Barré syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Guillain-Barré syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome medical therapy

CDC on Guillain-Barré syndrome medical therapy

Guillain-Barré syndrome medical therapy in the news

Blogs on Guillain-Barré syndrome medical therapy

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, MBBS [2]

Overview

With prompt treatment of plasmapheresis followed by immunoglobulins and supportive care, the majority of patients will regain full functional capacity. However, death may occur if severe pulmonary complications and dysautonomia are present.

Medical Therapy

  • Treatment for Guillan Barre syndrome can be divided into two groups:
    • Supportive therapy:
      • Respiratory assistance: WE measure maximal expiratory vital capacity and if vital capacity falls under 15 ml/kg we start mechanical ventilation and endotracheal intubation.
      • Heart rate and blood pressure monitoring.
      • Prevention of thromboembolic complications by heparin.
      • Reduce respiratory infections by minimal sedation in intensive care units.
      • Pain control by analgesics.
      • Prevention of contracture by early passive movement.
    • Immunomodulating therapy
      • Plasma exchange: It is proved in so many studies that plasma exchange is an effective treatment option and can reduce recovery time.[1][2]
      • High dose immunoglobulin: IVIG is as effective as plasma exchange for treatment of GBS. Combination therapy with these two will not result in a netter outcome.[3][4]
      • Corticosteroids:
        • In some animal models it was demonstrated that corticosteroids reduce allergic neuritis (62)
        • In another study it was demonstrated that treatment with corticosteroids alone is not effective. (61)
        • In a randomized study it was demonstrated that the combination of IVIG and corticosteroid will not result in any advantage. (64)

References

  1. "Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome". Ann. Neurol. 22 (6): 753–61. December 1987. doi:10.1002/ana.410220612. PMID 2893583.
  2. "Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome". Ann. Neurol. 32 (1): 94–7. July 1992. doi:10.1002/ana.410320115. PMID 1642477.
  3. van der Meché FG, Schmitz PI (April 1992). "A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group". N. Engl. J. Med. 326 (17): 1123–9. doi:10.1056/NEJM199204233261705. PMID 1552913.
  4. Dalakas MC (December 2002). "Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies". Neurology. 59 (12 Suppl 6): S13–21. PMID 12499466.

Template:WH Template:WS